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ABSTRACT 
Objective: The role of hormone receptors as a prognostic and therapeutic tool in breast cancer is widely accepted. The aim of this study was to the 
analysis of steroid receptor status in breast cancer with clinic pathological characteristics.  
Methods: In the present study, immunohistochemical assay of two hundred tumor block of patients of breast carcinoma was performed to know 
the hormone receptor status as well as histological examination.  
Results: 150 samples were grouped to study hormonal status and their relation with clinic-pathological factors. The results in the present study 
documented the 42.3 %, 37.6 % and 56.2 % expression rate of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor-2 (Her2/neu) (. The negative expression of ER, PR receptors found higher (57.7 %, 62.4 % respectively). However, Her2/neu 
positive expression found higher than negative expression (43.8 %). An inverse correlation of Her2/neu expression with ER and PR expression was 
observed (p=0.007). A significant association of tumor size was observed with ER and PR expression (p=0.02 & p=0.04 respectively). However, no 
statistically significant association was observed between Her2/neu expression and tumor size (p=0.84).<4 positive lymph nodes showed more no 
reactivity of the receptors (ER, PR & Her2/neu) than>4 positive lymph nodes. No significant association of lymph node status and histological types 
was found with receptor expression.  
Conclusion: In conclusion further functional analyzes of ER, PR and Her2 receptors are needed to investigate the effects of compounds in inhibiting 
cancer in humans. 
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INTRODUCTION 
Breast cancer is the most frequently occurring cancer in women, 
with around 1 million newly diagnosed cases each year worldwide 
and responsible for about 375,000 deaths in the year 2000 alone 
[1]. It is a heterogeneous disease with different subtypes and 
classified disease on the basis of hormone receptor status [2]. 
Different biomarkers are routinely used in the laboratory for 
diagnosis of breast cancer. These Biomarkers plays an increasingly 
important role in disease detection and treatment. Tumor 
biomarkers are the range of molecules from nucleic acids to 
metabolites. However, protein biomarkers convert most readily into 
targeted therapies (as most pharmaceuticals tend to target proteins) 
and clinical diagnostic assays using standard existing platforms [3].  
Breast cancer shows heterogeneity in its clinical behavior. 
Clinicopathological factors like tumor grade, size, lymph node status 
and histological type plays an important role in predicting prognosis 
and response or resistance to the therapy [4, 5].  
Determining the estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor-2 (Her2/neu) receptor 
status in breast cancer becomes medical practice nowadays. Clinical 
trials have also shown, the survival advantage for patients with 
hormones receptor positive status by treatment with adjuvant 
hormonal or chemotherapeutic regimens [6]. It is well known that 
strong ER-positive cases benefit from endocrine therapy alone, in 
contrast to those with low to moderate ER positivity [7]. PR status is 
independently associated with disease-free and overall survival. 
Patients with ER, PR positive tumors have a better prognosis than 
patients with negative expression of ER and PR tumors [8].  
Immunohistochemical analysis of these receptors is used for 
predictive purposes in routine breast cancer patient management. 
Reduction in the mortality will require successful strategies for early 
detection and screening of the disease. The present study aimed to 
evaluate the expression of estrogen, progesterone and Her2/neu 
receptors as biomarkers and their relation with clinicopathological 
factors in human breast carcinoma.  
MATERIALS AND METHODS 
Sample collection 
Two hundred tumor block of patients ranging in age from<40 to ≥60 
y were selected for this study from Pt. B. D. Sharma University of 
Heath Sciences Rohtak, Haryana. One hundred fifty samples were 
grouped to study hormonal status & their relation with 
clinicopathological factors whereas 50 samples showed the type of 
cancer other than hormone receptors subtype. Out of 150 samples, 
only 130 were evaluated for the histological and Immuno-
histochemical examination, 20 samples being omitted due to the 
incomplete information. All samples were taken after institutional 
ethical committee permissions and personal consent of the patients 
or guardians reg no. (CBT-360/4.4.12). 
Histological examination 
Histological assessment of tumor grade (low, intermediate, and high), 
tumor size (<2 cm, 2–4.9 cm, ≥5 cm) and lymph node status (positive 
or negative) were performed. Diagnosis age was categorized as<40, 
40–49, 50–59, and ≥60 y. The histological parameters of all cases were 
reviewed by a pathologist and the histological grades were 
determined for each case according to Nottingham modification of the 
Bloom and Richardson Grading System [9].  
Immunohistochemical scoring 
Tissue sections mounted on glass slides were collected. After 
deparaffinization in xylene, slides were rehydrated through the 
grades of alcohol. Endogenous peroxidase activity was blocked by 
using 2 % hydrogen peroxidase in methanol. Antigen retrieval was 
performed with heating the coated sections on glass slides in citrate 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 4, 2016 
Yadav et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 4, 287-290 
288 
buffer for 20 min. A mouse anti ER and PR monoclonal antibodies 
and a rabbit anti ErbB-2/Her-2 monoclonal antibody (Biogenex, 
USA, CA) were used as primary antibody. Horseradish peroxidase 
polymer (Biogenex, USA, CA) was used as secondary antibody. The 
sections were first stained with diaminobenzidine (DAB) and then 
using hematoxylin stain. The ER and PR results were screened 
manually and interpreted as positive or negative on the basis of 
scores for proportion as well as intensity. The expression of ER and 
PR was scored between 0 and 8, 0: (negative) no nuclei staining; 1: 
(borderline) 1 % of nuclei staining; 2: (positive) 1-10 % of nuclei 
staining; 3: (positive) 11-33 %; 4: (positive) 34-66 %; 5, 6 & 7: 
(positive) 100 % of nuclei staining. Expression of HER2/neu scored 
0 to 3 as follows: 0 (negative): no membranous staining identified, 1 
(negative): faint staining involving 10 % of positive cells; 2 
(positive): weak but definitive staining of the membrane over at 
least 10 % of positive cells; 3 (positive): strong positive staining of 
the complete membrane in more than 20 % of cells. 
Statistical analysis 
Chi-square test, Pearson correlation were performed using software 
SPSS 11.0 to find out the relation of ER/PR and Her2/neu expression 
with different clinic-pathological factors age, tumor size, grade, 
lymph node status. 
RESULTS 
In the present study, Immunohistochemical analysis of breast 
carcinoma samples was performed, and their relation to 
clinicopathological factors was studied in detail. The expression rate 
of ER, PR and Her2/neu receptors was observed 42.3 %, 37.6 % and 
56.2 % (fig. 1B, 1C & 1D). The negative expression of ER, PR 
receptors found higher (57.7 %, 62.4 % respectively) than the 
positive expression (fig. 1A). However, Her2/neu positive 
expression found higher than negative expression (43.8 %). An 
inverse correlation of Her2/neu expression with ER and PR 
expression was observed (p=0.007). In Her2/neu positive cases, the 
negative expression of ER and PR was found higher than positive 
expression (47.94 % & 46.57 %). 
 
 
Fig. 1: Microscopic images of the pattern of IHC×100 staining in 
breast carcinoma. (A) Negative expression of receptors (ER, PR 
& Her2/neu) (B) Nuclear stain of ER (C) Nuclear stain of PR (D) 
Cytoplasmic stains of Her2/neu 
 
Age 
Breast carcinoma patients were categorized in different age groups 
from less than 40 y to greater than 60 y. The mean age was 48 y. No 
statistically significant association was found in positive/negative 
expressions of ER, PR and Her2/neu and different age groups. The 
positive expression of ER, PR and Her2/neu found higher in old 
patients whereas negative expression of ER and Her2/neu found 
higher in patients younger patients. However negative expression of 
PR found both in old and young patients (fig. 2). 
 
 
Fig. 2: Distribution of receptor expression among different age groups 
 
Tumor grade 
The grading was based on cellular and nuclear pleomorphism, 
ductular differentiation, necrosis and infiltration of surrounding 
adipose tissue. Reactivity of receptors found more in grade II as 
compared to grade I and III. Positivity of ER, PR and Her2/neu was 
observed 24.62 %, 22.31 % and 27.7 % respectively in tumor grade 
II. Expression of ER and PR found to be significantly associated with 
tumor grade (p=0.001 and p=0.02) respectively. Whereas, Her2/neu 
expression did not reveal any significant association with tumor 
grade (p=0.94) (table 1). 
Tumor size 
The size of tumors ranged from 0.1 cm to 12 cm. Breast cancer 
samples with<2 cm tumor size were found to have a positive 
expression of ER and Her2/neu (22.3 % & 23.9 %) and negative 
expression of PR (23.1 %). On the other hand, samples with tumor 
size 2-4.9 cm were found to have a negative expression of ER, PR 
(26.93 % & 26.16 %) and positive expression of Her2/neu (24.6 %). 
Similarly, samples with tumor size>5 cm were found to have a 
negative expression of ER and PR (12.31 % & 13.1 %) and positive 
expression of Her2/neu (8.4 %). A significant association of tumor 
size was observed with ER and PR expression (p=0.02 & p=0.04 
respectively). However, no statistically significant association was 
observed between Her2/neu expression and tumor size (p=0.84) 
(table 1). 
Lymph node status 
Two parameters for metastasis were counted less than 4 and more 
than 4 lymph nodes. Breast cancer samples having<4 positive lymph 
nodes showed more non-reactivity of the receptors in comparison 
with>4 positive lymph nodes. 
Histological type 
Two Histological types i.e. infiltrate ductal carcinoma (IDC), and 
lobular carcinoma (LC) was found in the present study. The 
majority of the samples showed infiltrate ductal carcinoma type 
(93 %) and only a few were lobular carcinoma type (7 %). No 
significant association of histological types was found with 
receptor expression of ER, PR and Her2/neu (table 3). The 
majority of the infiltrate ductal carcinoma (IDC) cases were found 
to have negative expressions of ER and PR (53.84 % & 58.46 %) 
and positive expression of Her2/neu (55.38 %). However in 
lobular histological type, the majority of cases were ER+ve (4.62 
%), PR-ve (3.85 %) and Her2/neu+ve (6.15 %) (table1). 
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Table 1: Association of ER, PR and Her2/neu receptor expression with different clinicopathological factors 
Clinicopathological Factors ER+ve  ER-ve   PR+ve  PR-ve Her2/neu+ve Her2/neu-ve  
(N =55)  (N= 75)  p-value (N=49) (N=81)  p-value (N=73) (N=57) p-value 
Tumor grade 
I 22(16.93) 21(16.16) 0.001 20(15.38) 23(17.7) 0.02 27(20.77) 19(14.62) NS 
II 32(24.62) 35(26.93)  29(22.31) 40(30.77)  36(27.7) 26(20)  
III 1(0.77) 19(14.62)  2(1.54) 16(12.31)  12(9.24) 10(7.69)  
Tumor size          
<2 cm 29(22.3) 23(17.7) 0.02 23(17.7) 30(23.1) 0.04 31(23.9) 21(16.16) NS 
2-4.9 cm 22(16.93) 35(26.93)  21(16.16) 34(26.16)  32(24.6) 25(19.24)  
>5 cm 5(3.85) 16(12.31)  5(3.85) 17(13.1)  11(8.47) 10(7.69)  
Lymph node status          
<4 positive 33(25.39) 47(36.15) NS 32(24.6) 48(36.93) NS 45(34.61) 35(26.93) NS 
>4positive 22(16.93) 28(21.54)  17(13.1) 33(25.39)  28(21.54) 22(16.93)  
Histological type          
IDC 50(38.46) 70(53.84) NS 46(35.38) 76(58.46) NS 72(55.38) 46(35.38) NS 
Lobular 6(4.62) 4(3.1)  3(2.31) 5(3.85)  8(6.15) 4(3.1)  
Significance level, p<0.05 (χ2test); NS= Non-significant; ER= estrogen receptor; PR= progesterone receptor; HER-2/neu= Human epidermal growth 
factor receptor 2;+ve= positive; –ve, negative= Note: Data are given as number (percentage); N, Total number of patients (n)=130. The majority of 
the samples with<4 positive lymph nodes were found to have negative expressions of ER and PR (36.15 % & 36.93 %) and positive expression of 
Her2/neu (34.61 %). However, no statistically significant association was observed among expressions of ER, PR, Her2/neu and lymph node 
metastasis status (table 1). 
 
DISCUSSION 
Improved breast cancer treatment requires integration of clinical 
pathology and cancer biology which could affect patient outcome. 
ER, PR and her2/neu are well-established procedures in routine 
breast cancer management mainly as prognostic factors for adjuvant 
hormone therapy [10, 11]. Our results reveal the significant 
association of different clinicopathological factors with an 
expression of ER, PR and Her2/neu.  
In the present study, positive expression of ER, PR and Her2/neu was 
found to be 42.3 %, 37.6 %, and 56.2 % respectively which correlate 
well with other studies [12, 13]. Hormonal receptor status has shown 
that overall positivity rate for ER and PR was lower in India than that 
reported in Western literature. In European and American population, 
60–80 % patients were found with positive receptor expression [14]. 
This may be due to lower average age at diagnosis or racial difference. 
Our study described inverse correlation of Her2/neu expression with 
ER and PR expression (p=0.007) which is well correlated with other 
studies [15-17]. These results might reflect women who overexpress 
Her2/neu may be resistant to Tamoxifen.  
Overall negative expression of ER and PR found higher than positive 
expression similar to other studies [18]. Slamon et al. reported only 
20-30 % positive expression of Her2/neu in contrast to our study 
positive expression of Her2/neu found higher than negative 
expression [19]. In Her2/neu positive cases, it was observed that 
negative expression of ER and PR was higher than positive 
expression, most similar to other studies [16,20]. Furthermore, a 
variation in receptor positivity has been reported in Asian 
population [21,22]. In different age group study, results confirmed 
that the positive expression of ER, PR and Her2/neu receptors found 
higher in older patients similar to other studies [23]. Whereas 
negative expression of ER and Her2/neu found higher in young 
patients and PR-ve patients were found in both young and old age 
group’s contrast to some studies [24].  
The tumor grade II were more common in our study followed by 
grade III and I similar to other studies [13]. However, this is a 
contrast to some studies where well-differentiated breast cancer is 
more common than the poorly differentiated cancer [12, 24]. In our 
study, ER and PR correlated well with grade II (p=0.001 and p=0.02 
respectively), but Her2/neu expression did not reveal a significant 
association with tumor grade. Similar results were reported by other 
studies [25]. Tumor size is one of the important predictors of tumor 
behavior in breast cancer. Our results described the significant 
association of tumor size with an expression of ER and PR (p=0.02 & 
p=0.04) respectively. On the other hand, Her2/neu expression did 
not reveal any correlation with tumor size. These results are 
correlated well with other studies [17, 26, 27]. Our results 
confirmed that non-reactivity of hormonal receptors increases with 
increase in tumor size.  
The present study provides convincing evidence for a non-
significant association between expression of ER, PR, Her2/neu and 
lymph node metastasis. Similar results have been documented in 
many other studies [27, 28]. In contrast to our results, Tokatli et al. 
found a significant association of Her2/neu expression with 
increased positive lymph node metastasis status [29]. Some similar 
studies found that majority of lymph node positive patients found to 
have Her2/neu positive expression [30, 31]. Our results documented 
that<4 positive lymph nodes showed more no reactivity of the 
receptors (ER, PR & Her2/neu) than>4 positive lymph nodes which 
is in contrast to other studies [21, 24]. The majority of the samples 
in our study were with infiltrating ductal carcinoma type, and only a 
few were the lobular type. However, our study, as well as others, did 
not found a significant association among expression of ER, PR, 
Her2/neu and histological types [16].  
CONCLUSION 
Immunohistochemical analysis of ER, PR and Her2 receptors is 
widely available at a reasonable cost and is prognostic as well as 
somewhat predictive. Our study confirms that receptor expression 
of ER and PR found to be significantly associated with tumor grade 
and tumor size, whereas Her2/neu expression did not reveal such 
association. However, no association of ER, PR, Her2/neu 
expressions was observed with lymph node metastasis status and 
histological type of breast cancer. An inverse correlation of 
Her2/neu expression with ER and PR expression was also observed. 
These observations suggested that breast cancers seen in the Indian 
population may be biologically different from that encountered in 
Western practice. Further functional analyzes of ER, PR and Her2 
receptors are needed to investigate the effects of compounds in 
inhibiting cancer in humans. These results of findings could have 
clinical importance in breast cancer treatment.  
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